Hyperfine, Inc. - Class A Common Stock (HYPR)
1.2100
-0.0300 (-2.42%)
NASDAQ · Last Trade: Mar 24th, 3:03 AM EDT
Detailed Quote
| Previous Close | 1.240 |
|---|---|
| Open | 1.270 |
| Bid | 1.190 |
| Ask | 1.240 |
| Day's Range | 1.170 - 1.275 |
| 52 Week Range | 0.5327 - 2.220 |
| Volume | 666,871 |
| Market Cap | 85.75M |
| PE Ratio (TTM) | -2.327 |
| EPS (TTM) | -0.5 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 617,362 |
Chart
About Hyperfine, Inc. - Class A Common Stock (HYPR)
Hyperfine, Inc. is a healthcare technology company that specializes in the development of mobile MRI systems. Their innovative approach aims to make magnetic resonance imaging more accessible and convenient, particularly in settings outside traditional imaging facilities, such as hospitals and clinics. By utilizing a portable and easy-to-use MRI device, the company enhances the ability of healthcare providers to perform rapid diagnostic imaging, ultimately improving patient care and outcomes. Hyperfine is dedicated to transforming the way medical imaging is delivered, focusing on affordability, portability, and ease of use for medical professionals. Read More
News & Press Releases
Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $40 million loan facility to Hyperfine, Inc. (NASDAQ: HYPR) (“Hyperfine”), with an initial funding of $15 million at closing, and up to $25 million available to support future commercial growth.
By Horizon Technology Finance Corporation · Via Business Wire · March 23, 2026

Hyperfine (HYPR) Q4 2025 Earnings Call Transcript
Via The Motley Fool · March 19, 2026
Hyperfine Inc (NASDAQ:HYPR) Reports Q4 Revenue Beat, Narrower Loss, and Bullish 2026 Outlookchartmill.com
Via Chartmill · March 18, 2026
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2025 financial results and provided a business update.
By Hyperfine, Inc. · Via Business Wire · March 18, 2026
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, March 18, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
By Hyperfine, Inc. · Via Business Wire · March 5, 2026
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced results from the largest data set to date evaluating stroke detection with the Swoop® system. This data provides strong evidence supporting the use of AI-powered portable MRI for stroke detection in multiple clinical settings, including the emergency department.
By Hyperfine, Inc. · Via Business Wire · January 27, 2026
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced results from the NEURO PMR study, presented by Dr. Laszlo Mechtler at the American Society of Neuroimaging (ASN) Annual Meeting in San Juan, Puerto Rico on January 16, 2026.
By Hyperfine, Inc. · Via Business Wire · January 20, 2026
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the enrollment of the first patient in the Contrast PMR study, a prospective, multi-center clinical study designed to evaluate the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI. The study is intended to support a future FDA submission to expand the Swoop® system’s intended use to include gadolinium-based contrast agents, potentially unlocking new applications across multiple care settings.
By Hyperfine, Inc. · Via Business Wire · January 15, 2026
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced preliminary, unaudited revenue, net cash burn, and cash and cash equivalents for the fourth quarter and full year ended December 31, 2025.
By Hyperfine, Inc. · Via Business Wire · January 12, 2026
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the first peer-reviewed publication in Clinical Neuroimaging, demonstrating the positive economic impact of implementing the portable Swoop® MR imaging system in the acute care setting of the hospital.
By Hyperfine, Inc. · Via Business Wire · January 6, 2026
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the Swoop® system has received regulatory approval in India from the Central Drugs Standard Control Organization (CDSCO), opening access to advanced brain imaging in one of the world's largest and fastest-growing healthcare markets with a significant unmet need.
By Hyperfine, Inc. · Via Business Wire · December 17, 2025
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it has received FDA clearance for a new multi-direction diffusion-weighted imaging (DWI) software sequence. This advancement delivers substantially improved image quality and diagnostic confidence for stroke detection, marking a significant expansion of the Swoop® system's clinical capabilities in acute neurological care.
By Hyperfine, Inc. · Via Business Wire · December 15, 2025
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced plans to present at the upcoming Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4th at 8:10 am Eastern Time (ET).
By Hyperfine, Inc. · Via Business Wire · November 20, 2025
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the strengthening of the company’s initiatives to improve global brain health in underserved settings through a Gates Foundation grant of $3.7 million.
By Hyperfine, Inc. · Via Business Wire · November 19, 2025
Hyperfine (HYPR) reported mixed Q3 2025 results, missing revenue and EPS estimates. The stock fell as its Q4 revenue guidance also trailed analyst expectations.
Via Chartmill · November 13, 2025
Hyperfine (HYPR) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 13, 2025
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · November 13, 2025
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2025 financial results and provided a business update.
By Hyperfine, Inc. · Via Business Wire · November 13, 2025
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report full financial results for the third quarter 2025 on Thursday, November 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
By Hyperfine, Inc. · Via Business Wire · October 30, 2025
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced plans for clinical use expansion into the operating room environment, advancing its mission to make brain MRI more accessible across a diversity of care settings. The company plans to establish a foothold in the neurosurgical operating setting by launching a new study to build a body of clinical evidence for Swoop® system use in neurosurgical procedures.
By Hyperfine, Inc. · Via Business Wire · October 21, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · October 16, 2025
Via Benzinga · October 16, 2025
Via Benzinga · October 16, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · October 16, 2025